**Name of Journal: *World Journal of Gastrointestinal Oncology***

**Manuscript NO: 49764**

**Manuscript Type: Editorial**

**New era for pancreatic endoscopic ultrasound: From imaging to molecular pathology of pancreatic cancer**

Archibugi L *et al*. EUS for pancreatic cancer precision medicine

**Livia Archibugi, Sabrina Gloria Giulia Testoni, Miriam Redegalli, Maria Chiara Petrone, Michele Reni, Massimo Falconi, Claudio Doglioni, Gabriele Capurso, Paolo Giorgio Arcidiacono**

**Livia Archibugi, Sabrina Gloria Giulia Testoni, Maria Chiara Petrone, Gabriele Capurso, Paolo Giorgio Arcidiacono,** Pancreato-Biliary Endoscopy and EUS Division, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy

**Miriam Redegalli, Claudio Doglioni,** Pathology Department, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy

**Michele Reni,** Department of Medical Oncology, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy

**Massimo Falconi,** Pancreatic Surgery Department, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy

**ORCID number:** Livia Archibugi (0000-0003-3979-9553); Sabrina Testoni (0000-0002-0042-2583); Miriam Redegalli (0000-0002-5308-280X); Maria Chiara Petrone (0000-0002-1045-209X); Michele Reni ([0000-0002-6463-0293](https://orcid.org/0000-0002-6463-0293)); Massimo Falconi ([0000-0001-9654-7243](https://orcid.org/0000-0001-9654-7243)); Claudio Doglioni (0000-0002-4969-5216); Gabriele Capurso (0000-0002-0019-8753); Paolo Giorgio Arcidiacono (0000-0001-6692-7720).

**Author contributions:** Archibugi L and Testoni SGG contributed equally to the paper and share first authorship; Archibugi L, Testoni SGG, and Redegalli M performed the literature search and drafted the manuscript; Petrone MC, Doglioni C, Capurso G, and Arcidiacono PG critically revised the manuscript; Capurso G, Reni M, Falconi M, Doglioni C, Petrone MC, and Arcidiacono PG provided scientific guidance; all authors revised and approved the final version of this article.

**Supported by** Associazione Italiana Ricerca sul Cancro (AIRC), No. IG 17177

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author: Gabriele Capurso, MD, PhD, Chief Doctor,** Pancreato-Biliary Endoscopy and EUS Division, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan 20132, Italy. capurso.gabriele@hsr.it

**Telephone:** +39-02-26436548

**Fax:** +39-02-26435607

**Received:** June 15, 2019

**Peer-review started:** June 19, 2019

**First decision:** July 31, 2019

**Revised:** August 1, 2019

**Accepted:** August 20, 2019

**Article in press:** August 21, 2019

**Published online:** November 15, 2019

**Abstract**

With recent advances in molecular pathology and the development of new chemotherapy regimens, the knowledge of the molecular alterations of pancreatic ductal adenocarcinoma (PDAC) is becoming appealing for stratifying patients for prognosis and response to a defined treatment. Archival formalin-fixed, paraffin-embedded samples are a useful source of genomic deoxyribonucleic acid; nevertheless, most studies employed formalin-fixed, paraffin-embedded samples deriving from surgical specimens, which are therefore representative of <20% of PDAC patients. Indeed, the development of a reliable methodology for endoscopic ultrasound-guided tissue acquisition, stabilization, and analysis is crucial for the development of molecular markers for clinical use in order to achieve “personalized medicine”. With the development of new needles, this technique is able to retrieve a high quantity and quality of PDAC tissue that can be used not only for diagnosis but also for mutational and transcriptome evaluations and for the development of primary cell or tissue cultures. In the present editorial, we discuss the current knowledge regarding the use of endoscopic ultrasound as a tool to obtain samples for molecular analyses, its possible pitfalls, and its use for the development of disease models such as xenografts or organoids.

**Key words:** endoscopic ultrasound; pancreatic cancer; ribonucleic acid; deoxyribonucleic acid; mutation; molecular; organoid; profiling; personalized medicine

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Surgical formalin-fixed, paraffin-embedded samples are not representative of all pancreatic ductal adenocarcinoma patients and it has been proven that “pre-resection” fine-needle aspiration smears are a better DNA source. Therefore, endoscopic ultrasound (EUS) is the recommended method for obtaining a tumor’s molecular signature. However, important limitations of EUS-acquired samples are: Intratumoral heterogeneity, total amount of tumoral cells, and lesional-to-non-lesional cell ratio. Furthermore, sample handling and storage conditions might affect the efficiency of DNA and even more RNA extraction. The possibility to obtain sufficient material from EUS to generate patient-derived xenografts or organoids is also a “hot topic”. Thus, optimization and standardization of procedures for EUS-guided biopsy and molecular analyses are essential to allow “precision medicine” for pancreatic ductal adenocarcinoma.

**Citation:** Archibugi L, Testoni SGG, Redegalli M, Petrone MC, Reni M, Falconi M, Doglioni C, Capurso G, Arcidiacono PG. New era for pancreatic endoscopic ultrasound: From imaging to molecular pathology of pancreatic cancer. *World J Gastrointest Oncol* 2019; 11(11): 933-945

URL: https://www.wjgnet.com/1948-5204/full/v11/i11/933.htm

DOI: <https://dx.doi.org/10.4251/wjgo.v11.i11.933>

**Introduction**

Endoscopic ultrasound (EUS) was developed in the 1980s to improve ultrasound imaging of the pancreato-biliary system. The most significant technological development achieved by EUS along its history has been the linear probe, which allows a needle to be tracked in real time across the image plane into a target lesion and is the basis for all EUS-guided therapeutic procedures. Over the years, this technique has been implemented and is still ongoing today. Currently, EUS is considered an indispensable tool for the detection, characterization, and differential diagnosis of solid pancreatic lesions, including pancreatic ductal adenocarcinoma (PDAC)[1].

The reported sensitivity of EUS for detecting PDAC is between 94% and 100%[2,3]. Compared with multidetector computed tomography (MDCT), EUS can detect about 14% of pancreatic cancers that were missed on MDCT[3]. In particular, EUS performs better for the detection of tumors smaller than 20 mm, for which both magnetic resonance imaging (MRI) and computed tomography (CT) have higher miss rates[4-6]. A meta-analysis evaluated the performance of EUS in those patients without an obvious mass on MDCT but with clinical suspicion for a pancreatic malignancy, and showed a higher sensitivity of EUS for detecting a pancreatic neoplasm[7]. A direct comparison of imaging modalities in the modern era has shown that EUS identified pancreatic abnormalities in individuals considered to be at high risk for developing PDAC 43% of the time, compared with 33% and 11% for MRI and CT, respectively[8].

Besides its excellent performance in visualizing and diagnosing pancreatic lesions, EUS is mainly employed as part of the workup to obtain fine-needle aspiration (FNA) or fine-needle biopsy (FNB) material in patients suspected of having a primary tumor. Indeed, EUS-FNA has become the preferred method for acquiring tissue from pancreatic lesions, playing an essential role in the diagnostic algorithms in patients with a pancreatic mass. EUS-FNA is considered a safe procedure, and a large systematic review of more than 10,000 patients reported reassuringly low morbidity (0.98%) and mortality (0.02%) rates associated with EUS-FNA[9]. To optimize tissue retrieval and in order to obtain core specimens, larger needles able to retrieve an FNB sample have been developed. To this end, a number of histology needles with changes in tip needle designs have been explored. However, one recent meta-analysis, which included prospective, randomized controlled trials and retrospective studies, showed that there was no significant difference between histology FNB and standard FNA needles in terms of diagnostic adequacy and accuracy, but FNB needle was superior for providing adequate histological tissue compared to FNA[10].

In the past few years, the advent of new combination chemotherapy regimens also used in the neoadjuvant setting have led to improvement in patients’ survival in all PDAC stages. In addition, knowledge on molecular changes associated with the occurrence and progression of PDAC has increased in parallel with the availability of data on the stratification of patients’ prognosis and possibly of response to various treatments[11]. In this age of “personalized medicine”, the role of EUS for the management of PDAC is shifting from solely diagnosing the disease, staging it, and providing tissue for the diagnosis, towards acquiring material to obtain a detailed characterization of the tumor’s molecular signature, in order to select the most appropriate treatment. In the present editorial, we will discuss current knowledge regarding the use of EUS as a tool to obtain samples for molecular analyses and for the development of disease models.

***Feasibility and pitfalls in obtaining pancreatic cancer DNA and RNA by EUS***

Archival formalin-fixed, paraffin-embedded (FFPE) samples are a useful source of genomic DNA; nevertheless, most studies employing these samples derive from surgical specimens and are therefore representative of <20% of PDAC patients. Thus, the development of a reliable methodology for EUS-guided tissue acquisition (EUS-TA), stabilization, and analysis is crucial for the development of molecular markers for clinical use.

Currently, the molecular analysis of samples acquired through EUS is performed non-routinely, either to help identify a PDAC when the cytology is not diagnostic or experimentally to predict prognosis and plan a specific therapy. EUS samples are often considered bearing a low content and low quality of representative material compared to surgical resection samples. A former study back in 2014 found that only 12.4% of 169 EUS-FNA cell block specimens obtained from malignant solid pancreatic masses have adequate cellularity for theranostic studies[12].

However, this area has greatly improved in the past few years. Hartley *et al*[13] compared a “preresection” single FNA smear to two 5 µm curl of macrodissected FFPE taken from Whipple resections specimens. FNA smears resulted in an even better source of DNA, as, despite a similar nuclear area, FNA smears yielded greater DNA per nuclear area. KRAS codon 12 mutations were detected, in fact, in 77% of the samples compared to 57% of matched FFPE samples, with FNA retrieving a higher DNA yield compared to FFPE.

This also underlines that the way the sample is stocked might change the DNA extraction efficiency. In fact, Berry *et al*[14] proved how the KRAS mutation frequency in the same patients was significantly lower (45%) when using DNA extracted from EUS-FNA-derived FFPE blocks compared to EUS-FNA samples that were snap-frozen (80%). It is known, indeed, how formalin leads to protein-DNA cross-links and to degradation of nucleic acids. On the other hand, FNA samples are not formalin-fixed and retain whole nuclei.

Nevertheless, although EUS-FNA allows the extraction of DNA/RNA from the pancreatic sample, the absence of a pre-evaluation of this sample by a cytologist does not allow certainty regarding tumor cellularity in the sample. Some studies[15] have tried to overcome this limitation by performing parallel FNA and cytological evaluation of the same samples. Benesova *et al*[15] extracted DNA and RNA from FNA-acquired tissue (put in RNALater) and FN cytological (FNC) air-dried smear, with a selected area trimmed out, of same patients undergoing EUS-FNA with a 22 G needle. The overall amount of isolated DNA/RNA from EUS-FNC samples was lower compared to EUS-FNA samples (10 ng *vs* 147 ng, respectively, for DNA; 164 *vs* 642 ng, respectively, for RNA); however, the KRAS-mutant detection frequency in EUS-FNC samples was 90% compared to 78% in EUS-FNA samples.

Furthermore, a great disadvantage of FNA samples is the fact that the slides obtained by EUS-FNA are very few and must be destroyed in order to submit cellular material for DNA extraction. The quantity of DNA that can be extracted from a given tissue also depends on the shape of the tip and the size of the needle. A controversial topic is whether FNB might offer advantages over FNA for DNA or RNA extraction, which is a matter of debate. As Dreyerand colleagues[16] demonstrated, DNA and RNA analyses can be performed effectively on EUS-FNB samples, but the quantity of both DNA and RNA changes based on the type of needle adopted, resulting in the highest in their cohort when adopting SharkCore 22 G (2939 ng DNA yield and 481 ng RNA yield). However, their sampling collection and conservation methods (fresh frozen or FFPE) were not matched in the same patients and the quality of RNA was not reported.

Elhanafi *et al*[17] conducted a retrospective analysis of all patients undergoing FNA or FNB with genetic testing on pancreatic adenocarcinoma, both with 22 G needles (EUSN-3 Cook Medical *vs* SharkCore Medtronic). A total of 145 samples were obtained with FNA and 22 with FNB, and were prepared with thin Prep-prepared slides (Hologic, Inc., Bedford, MA, United States) and cell block specimens. A required minimum of 10% tumor cellularity was used as a limiting criterion to deem a sample sufficient, consistent with the prior literature. FNB samples were significantly more likely to have sufficient material for genomic testing compared to FNA samples (90.9% *vs* 66.9%; *P* = 0.02).

Another possible pitfall is represented by the presence of heterogeneity in terms of presence of cancer cells, with EUS-TA only retrieving a part of the lesion that might not contain malignant cells or only a small percentage. Therefore, if a part of the biopsy where cancer cells are absent is employed for molecular analysis, false negatives might occur. This aspect has not been investigated widely. Berry *et al*[14], however, reported that only 2.5% (1 out of 40) of their pancreatic cancer samples that were positive for tumor cells at cytology and harbored KRAS mutations resulted in negative findings for tumor markers in the transcriptional profile. These results suggest that this might not be a major limitation to the use of FNB samples for transcriptional analyses.

An important point is also the evaluation of the total amount of tumoral cells, which should be analyzed to assess the probable retrievable amount of DNA to have reproducible results with a given technique. Fabbri *et al*[18] reported their experience with a threshold of about 5 ng good quality DNA necessary to detect KRAS mutations using a mutation-specific technique, and about 5-10 ng for next-generation sequencing. Furthermore, considering that a neoplastic cell holds 10 pg of DNA, they hypothesized a minimum cut-off number of lesional cells of 1000 to retrieve more than 10 ng of DNA, thus allowing to obtain an adequate specimen.

Another important factor is the lesional-to-non-lesional cell ratio (or lesional cell enrichment) and the type of technique used for sequencing. In fact, Sanger sequencing bears a low analytical sensitivity and requires at least 30%-40% of lesional cell enrichment to detect mutations, while next-generation sequencing or mutation-specific techniques are able to detect mutated KRAS alleles with 1%-5% tumor cell enrichment[18].

Indeed, a possible pitfall for DNA and RNA testing on pancreatic samples retrieved with EUS-FNA or FNB is the suboptimal content of pancreatic cancer cells and contamination with other non-malignant tissues, such as blood, gastric or duodenal wall cells, based on where the EUS-TA was performed, and also immune cells. Nevertheless, Berry *et al*[14] showed how the leukocyte marker cluster of differentiation 45 is scarcely expressed, as is also duodenal or gastric cell markers’ messenger RNA (commonly known as mRNAs).

Specifically referring to RNA, the main issue in its extraction from pancreatic tumor tissue is the high quantity of endogenous RNA ribonuclease (commonly known as RNase) that degrades RNA upon tissue acquisition.

Very few studies have been published on the best methodology for RNA extraction from mice and human pancreatic tissue but none of them have included a defined methodology for RNA extraction from tissue acquired through EUS. Nevertheless, as reported above, this has to be the goal in the near future, in order to provide our patients a defined path at first diagnosis.

Berry *et al*[14] extracted both RNA and DNA using a 22 G needle (ProCore Cook), snap freezing (in liquid nitrogen) the tissue after cytological rapid on-site evaluation (commonly known as ROSE) to confirm the diagnosis. They evaluated the quantity and quality of the DNA and RNA extracted using different methods, among which was the EUS-FNA pass snap-frozen in liquid nitrogen, and then homogenized and divided into smaller aliquots prior to processing. This technique allowed for retrieval of an average of 12.9 ± 3.2 µg of RNA and 4.8 ± 3.7 µg of DNA. In terms of quality, however, this method retrieved RNA with an RNA integrity number around 3, which is suboptimal. Interestingly, yields of genomic DNA were approximately 10-fold higher when an additional EUS-FNA pass was performed.

On the other hand, microRNAs (miRNAs) are a highly stable type of RNA, which is probably the reason why they have been studied as much or even more than mRNA of pancreatic cancer tissues on EUS-FNA; also, recent studies have elucidated how they could represent potential early biomarkers for pancreatic tumor detection and that they may also serve as prognostic factors[19].

**SOMATIC MUTATIONAL ANALYSES FROM EUS-DERIVED PANCREATIC CANCER SAMPLES**

Somatic mutations in EUS-acquired tissue have been investigated, especially for KRAS and particularly for cases in which the cytology could not be a determinant in the diagnosis.

Trisolini *et al*[20] evaluated 89 pancreatic lesions having adequate cytology on EUS-FNA samples by using a sequential approach for detecting KRAS mutations using mutant enriched-PCR (commonly known as ME-PCR). In all cases, DNA was extracted from cell-blocks and KRAS mutations were investigated by RT-qPCR followed by ME-PCR in non-amplifiable and negative cases. This “two-step” approach, proposed to evaluate KRAS mutations in indeterminate and negative cytology samples, simulates a realistic diagnostic workflow. Using this approach, the authors obtained a sensitivity of 90.2% and specificity of 100%.

Park *et al*[21] also reported a remarkable increase of the diagnostic yield of EUS-TA on pancreatic tumors when analyzing cytology and KRAS mutation in combination, evaluated on the sample flushed from the needle.

Elhanafi *et al*[17] performed somatic genomic testing using a 47-gene comprehensive solid tumor panel for the FNA/FNB rinse material or on the cell-block material of 25 PDAC patients. KRAS mutations were present in 88% of cases, while TP53 was in 68% and SMAD4 in 16%. Overall, tumor profiling identified two or more mutations in 84% of tested patients and three or more mutations in 56% of tested patients. There was only a slight divergence of survival between patients with wild-type TP53 and those with a mutated status, although that finding was not statistically significant.

Yoon *et al*[22] compared, for the same patients, baseline (from EUS-FNA FFPE) and after-treatment (from surgical specimen) somatic mutational profiles of 409 genes for seven patients. Results showed that after treatment, survival was worse in those harboring ARID1A mutations than those who harbored the wild-type, and that TP53 and KRAS mutations were not associated with survival. Also, KRAS mutations were present less frequently in specimens after treatment than at baseline, possibly representing a selection of less aggressive clones by chemotherapy.

A recent study by Dreyer *et al*[16] used genetic testing of a panel of 54 genes for 42 patients (including mostly PDAC cases, but also cases of other pancreatic lesions) using FNB samples and revealed mutations in KRAS (93%), GNAS (14%), TP53 (78%), CDKN2A (34%), and SMAD4 (32%), as well as in BRCA1(6%), ATM (12%), and BRAF (12%).

These studies collectively demonstrate that EUS-TA provides material that is adequate for mutational analyses of either single genes or of panels of genes. The optimal sample preparation in terms of needles, tissue conservation and handling is, however, unclear. Moreover, whether these genomic changes might change over time, over the course of the disease, and under treatments has been poorly investigated.

**FEASIBILITY AND CLINICAL UTILITY OF PANCREATIC EUS-FNA/FNB FOR OBTAINING RNA-BASED MOLECULAR PROFILE**

The PDAC microenvironment is characterized by a dense stromal compartment, comprising myofibroblast/cancer-associated fibroblastic cells, immune cells, and soluble factors, such as cytokines, chemokines, growth factors, and pro-angiogenic factors. This variable composition for different cellularity is a major limitation in the assessment of genetic mutations through tissue DNA-based analysis to allow classification of malignant and benign tissues, prediction of clinical outcomes, or selection of patient-specific treatments. In contrast, assessment of RNA expression level, protein level, or post-translational modifications could overcome the DNA analysis-related limitations. In fact, it is thought that PDAC heterogeneity is regulated at the epigenetic and transcriptomic levels and, therefore, clinical outcome and sensitivity to therapy could be associated with a given tumor phenotype. This would be important mostly for patients that are not eligible for surgery. Gene expression level can be measured by analyzing mRNA, the precursor of protein synthesis, using DNA microarray platforms, or RNA sequencing (RNAseq)[23].

Transcriptome analysis using cDNA microarrays has been shown to have a high yield for distinguishing benign from malignant lesions. Several studies have shown the feasibility of RNA extraction from EUS-FNA/FNB samples and the clinical utility to perform transcriptome analysis to improve the diagnostic accuracy of EUS-FNA/FNB. Significant overexpression of keratin 7 (KRT7), lipocalin 2, and tissue-type plasminogen activator genes in PDAC, as shown in PDAC cell lines and specimens, was also observed in EUS-FNA samples[24]. A molecular signature based on S100P (calcium binding protein P) and KRT7 expression was significantly associated with a better discriminatory capacity of PDAC from pseudotumoral inflammatory lesions[25]. In EUS-FNA samples, the quantification of expression of other several biomarkers, such as calcium binding proteins S100A6 and S100A4[26], urokinase plasminogen activator receptor[27] combined with a 6-gene classifier (EpCAM2, Mal2, CEA5, CEA6, MSLN, and Trim29), and DNA mismatch excision repair gene MSH6[28], showed a high sensitivity and specificity for the diagnosis of PDAC and differential diagnosis with benign diseases. Other less investigated markers, but helpful to improve the diagnosis of PDAC on EUS-FNA samples, were revealed to be the transcription factor Snail, which mediates epithelial-mesenchymal transition and was significantly associated with invasive characteristics[29], as well as pancreatic duodenal homeobox-1 (PDX-1)[30].

Other factors implicated in tumor invasiveness quantifiable in EUS-FNA samples are vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), involved in tumor angiogenesis, even if in one study RNA concentration and quality were relatively low in most samples. Both VEGF and EGFR were significantly overexpressed in PDACs and not significantly in pancreatic neuroendocrine tumors compared with normal pancreatic tissue. Moreover, EGFR expression was related to invasiveness in PDACs, whereas VEGF was inversely associated with tumor size[31]. On the other hand, Costache *et al*[32] found that mRNA expression of VEGF receptors VEGF-R1 and VEGF-R2 was significantly correlated with a shorter survival than VEGF-R-negative patients; as well, co-expression of VEGF-R1 and VEGF-R2 was found to be a poor prognostic factor in PDAC. Confirmation of the validity of EUS-FNA samples as a source of tissue for molecular analysis was given by a study performed by Steg *et al*[33], in which a significant concordance in the molecular profiles of hedgehog (HH)-pathway genes, potential mediators of pancreatic carcinogenesis, in matched snap-frozen, archival FFPE, and EUS-FNA samples, was observed. However, tissue heterogeneity and minimum content of cancer cells in PDAC EUS-FNA samples represented major obstacles in molecular analysis[33,34], as confirmed by significantly different expression of HH signaling-associated markers compared to uninvolved pancreatic tissue. Laser capture microdissection on FFPE samples from EUS biopsies with cancer-cell enriched samples improved qRT-PCR analysis. Moreover, EUS-FNA biopsies could be used for multiple sampling to determine the modulation of gene expression with treatment, even if no significant changes in HH-pathway gene expression were observed in EUS-FNA samples obtained before and 2 wk after the administration of capecitabine and radiation[33].

The function of pancreatic intratumoral infiltrating immune cells is still not well understood. To the best of our knowledge, there is only one study that assessed the infiltrating immune cells in EUS-FNB samples, applying qRT-PCR analysis[35]. Patients with a highly immunosuppressive profile tended to have a poor postoperative survival. A combination of CD15+ (neutrophils), CD206+ (tumor-associated macrophages), CD117+ (mast cells), and SMAD4 expression was independently associated with overall and recurrence-free survival.

A major limitation of cDNA microarrays is the amount of RNA required. RNAseq has the advantage of requiring only 100 ng of total RNA for reliable and reproducible transcriptome results. The application of this molecular technique on EUS-FNA samples is still rare and is currently under investigation. EUS-FNA was shown to provide sufficient material for targeted capture transcriptome RNAseq in the majority of specimens, using only a portion of a single FNA pass. RNAseq can be used to develop a classifier profile consisting of differentially expressed genes and separate benign from malignant pancreatic tissue in 83% of cases[23]. Moreover, RNAseq was able to segregate patients into clinically relevant phenotypic subtypes (squamous and classical PDAC) in both pancreatic primary and liver metastatic lesions, showing the same subtype cluster in primary and metastatic disease[16].

There has also been increasing interest in miRNAs recently; these small chains of non-coding RNA are negatively involved in the post-transcriptional regulation of gene expression. Several studies have described an aberrant production of miRNAs during the development of precancerous lesions (pancreatic intraepithelial neoplasia and intraductal papillarymucinous neoplasms) and in pancreatic carcinogenesis, and defined several miRNA signatures associated with diagnosis, staging, progression, prognosis, and response to treatment. Few studies have attempted quantification of miRNAs on pancreatic EUS-FNA samples, and have mainly involved FFPE samples. MiRNAs could still be quantified, even in low amounts and highly degraded samples.

MiRNAs were first tested on EUS-FNA samples by Szafranska *et al*[36]. The authors found that the expression of a miR-196a/miR-217 classifier could discriminate PDAC from benign lesions with a sensitivity and specificity of 90% and 100%, respectively. Subsequently, the same group found a better 2-miRNA classifier (miR-135b/miR-24) for PDAC[37]. The tissue miR-21/miR-155 classifier was a strong independent predictor of PC when up-regulated, with higher discriminating power compared to cytology and to the same classifier on plasma[38]. Also, high levels of miR-21 in EUS-FNA samples of unresectable PDAC were associated to progression and reduced survival[39]. Also, miR-10b was overexpressed in PDAC EUS-FNA material, and its reduced expression was associated with an improved response to neoadjuvant therapy, surgical resection, increased time to metastasis onset, and increased survival[40]. Inthat study, evaluation of miRNA expression changes was performed using a combination of fluorescence *in situ* hybridization/immunohistochemistry (IHC) assay in FFPE samples, on CK19-stained suspicious cells. In addition to well-established onco-miR-21 and -miR-10b, overexpression of other miRNAs (miR-221, miR-196a, miR-135b, miR-24, miR-130, miR-148a, and miR-93) in FFPE cell-blocks from EUS-FNA was also able to improve detection of PDAC and malignant pancreatic cysts from benign cases (accuracy up to 90.8%) when combined with standard cytology[41-44]. As for other molecules, heterogeneity in miRNA profiles from EUS-FNA samples has been reported possibly due to the different techniques used to collect samples, isolate total RNA, and quantify miRNA levels. Contaminating elements may also provide significantly different miRNA expression. Thus, it has been hypothesized that analysis of cytological smears from EUS-FNA would be a better approach for the determination of miRNA levels as this would allow a precise evaluation of the fraction and representation of tumor cells. As mentioned before, Benesova *et al*[15] showed how the overall amount of RNA extracted from air-dried cytological smears was lower compared to tissue acquired with EUS-FNA and put in RNALater, but gave reliable results with clinical validity (*i.e*., prognostic role of miR-21).

**FEASIBILITY AND CLINICAL UTILITY OF PANCREATIC ENDOSCOPIC ULTRASOUND-FINE NEEDLE ASPIRATION/FINE NEEDLE BIOPSY FOR ASSESSMENT OF TREATMENT EFFICACY**

Selecting patients who are likely to respond positively to a specific treatment may help to improve the prognosis of patients with unresectable PDAC. Characterization of genes associated to tumor sensitivity or resistance to antitumor therapeutic factors using pre-treatment tumor tissue would help clinicians for the selection of appropriate treatment regimen and the development of individualized treatment. Few studies assessed potential biomarkers predictive of chemosensitivity and modifications of specific biomarkers during treatment on EUS-FNA/FNB samples.

Expression of HSP72 on EUS-FNA samples, evaluated through IHC, was significantly associated with that on resected specimens and was a helpful predictive marker for sensitivity to gemcitabine (GEM). GEM-resistance rate was significantly higher in patients with overexpression of p-HSP27, and the survival rate was significantly lower if p-HSP27 (Ser82) detection rate was > 51.6%[45]. Another important molecular biomarker for prediction of GEM sensitivity in unresectable PDAC was S100A4 mRNA expression, analyzed in EUS-FNA samples through qRT-PCR analysis. High expression of S100A4 mRNA was a predictor of GEM resistance, in contrast to low S100A mRNA expression levels in the effective patient group[46]. Also, human equilibrative nucleoside transporter 1 (hENT1), a mediator of GEM uptake in human cells[47], deoxycitidine kinase (dCK), a GEM metabolism-related enzyme[48], and ribonucleoside reductase 1 (RRM1)[49] and ribonucleoside reductase 2 (RRM2)[50], GEM resistance-related enzymes, have been investigated for their role as predictive biomarkers for GEM effect and sensitivity in unresectable PDAC patients. Expression levels of these genes in EUS-FNA samples were detectable, even if with discordant data. The predictive yield of hENT1 for GEM sensitivity and prognosis in unresectable pancreatic cancer was confirmed by Yamada *et al*[51], who performed IHC assessment on preoperative EUS-FNB, according to their finding of concordant hENT1 expression with that found in resected specimens, thus providing important information on patients who could benefit from curative-intent resection. In fact, a significantly better prognosis was found in hENT1-positive patients than in those who were hENT1-negative. Also, a high level of RRM2 mRNA expression was correlated with a poor response rate to GEM and shorter overall survival[50]. Analysis of mRNA expression of hENT1, dCK, RRM1, and RRM2 genes in microdissected cancer cells from EUS-FNA samples of patients receiving preoperative GEM-based chemoradiotherapy showed potential as a tool to perform individualized chemotherapy[52]. In that study, laser capture microdissection of cancer cells revealed itself to be a molecular RNA-based method capable of overcoming the limitations presented by the large amount of blood and inflammatory cells and scarce cancer cells in most EUS-FNA samples. The same group measured EGFR mRNA levels in EUS-FNA samples successfully by using laser microdissected neoplastic cells[53]. High EGFR mRNA expression was found to be an independent prognostic factor in patients treated with GEM-based adjuvant chemotherapy, suggesting that quantification of EGFR mRNA expression levels could be a valuable tool to predict PDAC patient outcome, even when samples contained abundant contaminating cells. Yet another study attempted to assess the effect of capecitabine with concomitant radiotherapy (XRT) in patients with locally advanced pancreatic cancer. In these patients, mRNA expression of thymidine phosphorylase, dihydropyrimidine dehydrogenase, and tumor necrosis factor-α was quantitated in EUS-FNA samples obtained 1 wk before and 2 wk after chemo-XRT[54], but no significant difference was found in the mRNA expression levels between pre- and post-XRT.

**EUS AS A TOOL TO GENERATE PATIENT-DERIVED XENOGRAFTS OR ORGANOIDS**

PDAC aggressiveness is related to its genomic instability and heterogeneity. Patient-derived xenograft (PDX) mouse models, also known as “avatar models”, may represent a promising tool to personalize pancreatic cancer treatments[55]. The construction of PDX models from surgical specimens is extremely limited for PDAC patients, as only 10%-15% of them present with localized resectable tumors[56]. Addressing this issue, Allaway and colleagues[57] succeeded in establishing PDXs from EUS-FNA biopsies of treatment–naïve primary pancreatic tumors. In addition, they performed genomic characterization of these models, revealing clinically relevant mutations (*e.g.,* KRAS, TP53, BRAF, and EGFR). Similarly, Berry and colleagues[14] established a preclinical PDX model from two patients diagnosed with pancreatic cancer, one expressing KRAS wild-type and the other KRAS mutant, to assess the sensitivity of these patients to the anti-EGFR inhibitor panitumumab. Even if PDX models can be useful for predicting drug response, their application in medicine is limited, as they are expensive and time- and resource-consuming, the engraftment rates can be as low as 20%, and tumor formation requires at least 12 wk[58].

Tumor organoids are three-dimension cultures of cancer cells and they can be derived from each patient, providing an individualized model. Compared to PDX models, tumor organoids are established more easily, having a success rate of 70%-80%[59]. For these reasons, patient-derived organoids (PDOs) are now considered the best model to evaluate the molecular profile and chemosensitivity of different tumors in a rapid and high-throughput manner.

In 2017, Tiriac and colleagues[60] succeeded in creating organoids from PDAC specimens obtained by EUS-FNB sampling using a 22 G needle. They managed to establish organoids from the majority of patients (87%) within 2 wk from the EUS procedure and successfully propagated 66% of them for five passages.

An elegant work from Seino and colleagues[61] showed the possibility to take advantage of PDOs to deeply investigate the biological behavior of different pancreatic cancer subtypes. The investigators produced 39 lines of PDOs from surgical, FNA, and ascites specimens and performed genomic and transcriptomic analyses. As a result, they demonstrated that the mutational profile determined the requirements of organoids for niche-specific factors to survive *in vitro* and *in vivo*.

More recently, PDOs were obtained from primary tumors and metastases by Tiriac and colleagues[62] to study the phenotype of different lesions for the purpose of finding biomarkers for treatment response. Indeed, the investigators generated a total of 114 PDO cultures from 101 patients, with 72% of FNB samples and 78% of resected specimens propagated for at least five passages, respectively. First, they evaluated the genomic and transcriptomic landscapes of the PDO library by whole-exome sequencing and RNA sequencing. Then, they performed “pharmacotyping” on 66 PDAC PDOs to assess the sensitivity to chemotherapeutic agents commonly used to treat pancreatic cancer; the results highlighted the strong concordance between patient outcome and the chemosensitivity of PDOs. In addition, the possibility to repeat biopsies longitudinally gave the opportunity to follow the clinical course for a patient. The PDOs generated at diagnosis exhibited the same response to treatments as the primary tumor; at disease progression, the investigators isolated organoids, which showed resistance to the chemotherapeutic agents employed in the previous regimen.

To date, few groups are exploiting EUS-FNB to generate PDAC PDOs. However, these studies set a milestone by developing and optimizing a procedure for isolating and propagating PDOs from a minimal quantity of tissue acquired by EUS-FNB sampling. Of course, PDOs do not recapitulate the complexity of tumor microenvironment because they lack immune cells, blood vessels, and all the stromal components, which play fundamental roles in PDAC biology. Nevertheless, the unique opportunity to follow the evolution of tumors longitudinally, thanks to a minimally invasive sampling procedure, may open new routes to precision medicine. Seufferlein and Kleger[63] believe in “organoidomics” as a promising tool to improve the management of PDAC patients and to deepen our knowledge of pancreatic cancer.

**CONCLUSION**

In the past few years, a number of important changes in the care of PDAC patients have occurred: (1) It seems that the majority of patients benefit from combination chemotherapy[64], when the patients are fit and can tolerate it; (2) The possibility that both germline and somatic mutations can predict the response to certain treatments is being investigated and might offer important routes for treatment personalization[65]; (3) Different molecular subtypes of PDAC exist with peculiar genomic and transcriptomic features and distinct clinical behavior[66]; and (4) Novel models that might help in investigating the molecular features and the chemosensitivity of the patients (avatar or organoids) almost in real time have been developed. In this scenario, the role of EUS as a tool to obtain tissue from the tumor at diagnosis in a scarcely invasive manner, possibly at multiple timepoints during the course of disease, is increasing. When reviewing the available literature on the topic, however, it is clear that the major problem regards the lack of standardization, optimization, and thus repeatability of the employed techniques (Table 1), starting from the choice of needles and going to the handling of samples. A close collaboration among endoscopists, clinicians, pathologists, and basic scientists is necessary to fill these gaps. In addition, it is important that these techniques are employed in a translational research environment where physicians/scientists can develop research questions that are clinically relevant and of immediate utility for patients.

**References**

1 **Hunt GC**, Faigel DO. Assessment of EUS for diagnosing, staging, and determining resectability of pancreatic cancer: a review. *Gastrointest Endosc* 2002; **55**: 232-237 [PMID: 11818928 DOI: 10.1067/mge.2002.121342]

2 **Palazzo L**, Roseau G, Gayet B, Vilgrain V, Belghiti J, Fékéte F, Paolaggi JA. Endoscopic ultrasonography in the diagnosis and staging of pancreatic adenocarcinoma. Results of a prospective study with comparison to ultrasonography and CT scan. *Endoscopy* 1993; **25**: 143-150 [PMID: 8491130 DOI: 10.1055/s-2007-1010273]

3 **Agarwal B**, Abu-Hamda E, Molke KL, Correa AM, Ho L. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. *Am J Gastroenterol* 2004; **99**: 844-850 [PMID: 15128348 DOI: 10.1111/j.1572-0241.2004.04177.x]

4 **Khashab MA**, Yong E, Lennon AM, Shin EJ, Amateau S, Hruban RH, Olino K, Giday S, Fishman EK, Wolfgang CL, Edil BH, Makary M, Canto MI. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. *Gastrointest Endosc* 2011; **73**: 691-696 [PMID: 21067742 DOI: 10.1016/j.gie.2010.08.030]

5 **Dewitt J**, Devereaux BM, Lehman GA, Sherman S, Imperiale TF. Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. *Clin Gastroenterol Hepatol* 2006; **4**: 717-25; quiz 664 [PMID: 16675307 DOI: 10.1016/j.cgh.2006.02.020]

6 **Xu MM**, Sethi A. Imaging of the Pancreas. *Gastroenterol Clin North Am* 2016; **45**: 101-116 [PMID: 26895683 DOI: 10.1016/j.gtc.2015.10.010]

7 **Krishna SG**, Rao BB, Ugbarugba E, Shah ZK, Blaszczak A, Hinton A, Conwell DL, Hart PA. Diagnostic performance of endoscopic ultrasound for detection of pancreatic malignancy following an indeterminate multidetector CT scan: a systemic review and meta-analysis. *Surg Endosc* 2017; **31**: 4558-4567 [PMID: 28378082 DOI: 10.1007/s00464-017-5516-y]

8 **Canto MI**, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, Topazian M, Takahashi N, Fletcher J, Petersen G, Klein AP, Axilbund J, Griffin C, Syngal S, Saltzman JR, Mortele KJ, Lee J, Tamm E, Vikram R, Bhosale P, Margolis D, Farrell J, Goggins M; American Cancer of the Pancreas Screening (CAPS) Consortium. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. *Gastroenterology* 2012; **142**: 796-804; quiz e14-5 [PMID: 22245846 DOI: 10.1053/j.gastro.2012.01.005]

9 **Wang KX**, Ben QW, Jin ZD, Du YQ, Zou DW, Liao Z, Li ZS. Assessment of morbidity and mortality associated with EUS-guided FNA: a systematic review. *Gastrointest Endosc* 2011; **73**: 283-290 [PMID: 21295642 DOI: 10.1016/j.gie.2010.10.045]

10 **Machicado JD**, Thosani N, Wani S. Will Abandoning Fine-Needle Aspiration Increase Diagnostic Yield From Tissues Collected During Endoscopic Ultrasound? *Clin Gastroenterol Hepatol* 2018; **16**: 1203-1206 [PMID: 29684460 DOI: 10.1016/j.cgh.2018.04.021]

11 **Zhen DB**, Coveler A, Zanon S, Reni M, Chiorean EG. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma. *Semin Oncol* 2018; **45**: 107-115 [PMID: 30391013 DOI: 10.1053/j.seminoncol.2018.05.004]

12 **Navina S**, McGrath K, Chennat J, Singh V, Pal T, Zeh H, Krasinskas AM. Adequacy assessment of endoscopic ultrasound-guided, fine-needle aspirations of pancreatic masses for theranostic studies: optimization of current practices is warranted. *Arch Pathol Lab Med* 2014; **138**: 923-928 [PMID: 24978918 DOI: 10.5858/arpa.2013-0335-OA]

13 **Hartley CP**, Mahajan AM, Selvaggi SM, Rehrauer WM. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples. *Cancer Cytopathol* 2017; **125**: 838-847 [PMID: 29024530 DOI: 10.1002/cncy.21935]

14 **Berry W**, Algar E, Kumar B, Desmond C, Swan M, Jenkins BJ, Croagh D. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors. *Int J Cancer* 2017; **140**: 2331-2343 [PMID: 28198009 DOI: 10.1002/ijc.30648]

15 **Benesova L**, Halkova T, Bunganic B, Belsanova B, Zavoral M, Traboulsi E, Minarik M. Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer. *Pathol Oncol Res* 2018; [PMID: 30361898 DOI: 10.1007/s12253-018-0490-9]

16 **Dreyer SB**, Jamieson NB, Evers L, Duthie F, Cooke S, Marshall J, Beraldi D, Knight S, Upstill-Goddard R, Dickson EJ, Carter CR, McKay CJ, Biankin AV, Chang DK. Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. *Chin Clin Oncol* 2019; **8**: 16 [PMID: 31070037 DOI: 10.21037/cco.2019.04.06]

17 **Elhanafi S**, Mahmud N, Vergara N, Kochman ML, Das KK, Ginsberg GG, Rajala M, Chandrasekhara V. Comparison of endoscopic ultrasound tissue acquisition methods for genomic analysis of pancreatic cancer. *J Gastroenterol Hepatol* 2019; **34**: 907-913 [PMID: 30422342 DOI: 10.1111/jgh.14540]

18 **Fabbri C**, Gibiino G, Fornelli A, Cennamo V, Grifoni D, Visani M, Acquaviva G, Fassan M, Fiorino S, Giovanelli S, Bassi M, Ghersi S, Tallini G, Jovine E, Gasbarrini A, de Biase D. Team work and cytopathology molecular diagnosis of solid pancreatic lesions. *Dig Endosc* 2017; **29**: 657-666 [PMID: 28190274 DOI: 10.1111/den.12845]

19 **Abreu FB**, Liu X, Tsongalis GJ. miRNA analysis in pancreatic cancer: the Dartmouth experience. *Clin Chem Lab Med* 2017; **55**: 755-762 [PMID: 28343174 DOI: 10.1515/cclm-2017-0046]

20 **Trisolini E**, Armellini E, Paganotti A, Veggiani C, Bozzola C, Frattini M, Pizio C, Mancuso G, Andorno S, Boldorini R. KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy. *Pathology* 2017; **49**: 379-386 [PMID: 28450086 DOI: 10.1016/j.pathol.2016.12.348]

21 **Park JK**, Lee YJ, Lee JK, Lee KT, Choi YL, Lee KH. KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma. *Oncotarget* 2017; **8**: 3519-3527 [PMID: 27974679 DOI: 10.18632/oncotarget.13864]

22 **Yoon KA**, Woo SM, Kim YH, Kong SY, Lee MK, Han SS, Kim TH, Lee WJ, Park SJ. Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment. *Gut Liver* 2019;[PMID: 30970447 DOI: 10.5009/gnl18355]

23 **Rodriguez SA**, Impey SD, Pelz C, Enestvedt B, Bakis G, Owens M, Morgan TK. RNA sequencing distinguishes benign from malignant pancreatic lesions sampled by EUS-guided FNA. *Gastrointest Endosc* 2016; **84**: 252-258 [PMID: 26808815 DOI: 10.1016/j.gie.2016.01.042]

24 **Laurell H**, Bouisson M, Berthelemy P, Rochaix P, Dejean S, Besse P, Susini C, Pradayrol L, Vaysse N, Buscail L. Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. *World J Gastroenterol* 2006; **12**: 3344-3351 [PMID: 16733850 DOI: 10.3748/wjg.v12.i21.3344]

25 **Bournet B**, Pointreau A, Souque A, Oumouhou N, Muscari F, Lepage B, Senesse P, Barthet M, Lesavre N, Hammel P, Levy P, Ruszniewski P, Cordelier P, Buscail L. Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. *Pancreatology* 2012; **12**: 27-34 [PMID: 22487470 DOI: 10.1016/j.pan.2011.12.003]

26 **Zihao G**, Jie Z, Yan L, Jing Z, Jing C, Xue L, Jing Z, Heng LW, Ru G, Jianyu H. Analyzing S100A6 expression in endoscopic ultrasonography-guided fine-needle aspiration specimens: a promising diagnostic method of pancreatic cancer. *J Clin Gastroenterol* 2013; **47**: 69-75 [PMID: 22914344 DOI: 10.1097/MCG.0b013e3182601752]

27 **Chen Y**, Zheng B, Robbins DH, Lewin DN, Mikhitarian K, Graham A, Rumpp L, Glenn T, Gillanders WE, Cole DJ, Lu X, Hoffman BJ, Mitas M. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. *Int J Cancer* 2007; **120**: 1511-1517 [PMID: 17192896 DOI: 10.1002/ijc.22487]

28 **Gheonea DI**, Ciurea ME, Săftoiu A, Ioana M. Quantitative RT-PCR analysis of MMR genes on EUS-guided FNA samples from focal pancreatic lesions. *Hepatogastroenterology* 2012; **59**: 916-920 [PMID: 22020914 DOI: 10.5754/I11463]

29 **Wang Z**, Zhao L, Xiao Y, Gao Y, Zhao C. Snail transcript levels in diagnosis of pancreatic carcinoma with fine-needle aspirate. *Br J Biomed Sci* 2015; **72**: 107-110 [PMID: 26510265 DOI: 10.1080/09674845.2015.11666805]

30 **Marzioni M**, Germani U, Agostinelli L, Bedogni G, Saccomanno S, Marini F, Bellentani S, Barbera C, De Minicis S, Rychlicki C, Santinelli A, Ferretti M, Di Maira PV, Baroni GS, Benedetti A, Caletti G, Lorenzini I, Fusaroli P. PDX-1 mRNA expression in endoscopic ultrasound-guided fine needle cytoaspirate: perspectives in the diagnosis of pancreatic cancer. *Dig Liver Dis* 2015; **47**: 138-143 [PMID: 25454709 DOI: 10.1016/j.dld.2014.10.010]

31 **Angelescu R**, Burada F, Angelescu C, Gheonea DI, Iordache S, Mixich F, Ioana M, Săftoiu A. Expression of vascular endothelial growth factor and epidermal growth factor receptor in pancreatic ductal adenocarcinomas, neuroendocrine tumours and chronic pancreatitis. *Endosc Ultrasound* 2013; **2**: 86-91 [PMID: 24949370 DOI: 10.4103/2303-9027.117692]

32 **Costache MI**, Iordache S, Costache CA, Dragos E, Dragos A, Saftoiu A. Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma. *J Gastrointestin Liver Dis* 2017; **26**: 51-57 [PMID: 28338114 DOI: 10.15403/jgld.2014.1121.261.eus]

33 **Steg A**, Vickers SM, Eloubeidi M, Wang W, Eltoum IA, Grizzle WE, Saif MW, Lobuglio AF, Frost AR, Johnson MR. Hedgehog pathway expression in heterogeneous pancreatic adenocarcinoma: implications for the molecular analysis of clinically available biopsies. *Diagn Mol Pathol* 2007; **16**: 229-237 [PMID: 18043287 DOI: 10.1097/PDM.0b013e31811edc7e]

34 **Brais RJ**, Davies SE, O’Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP, Neesse A, Lockley M, Corrie PG, Jodrell DI, Praseedom RK, Huguet EL, Jah A, Jamieson NV, de Sauvage FJ, Tuveson DA, Carroll NR. Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. *Pancreatology* 2012; **12**: 8-15 [PMID: 22487467 DOI: 10.1016/j.pan.2011.12.009]

35 **Wang WQ**, Liu L, Xu HX, Wu CT, Xiang JF, Xu J, Liu C, Long J, Ni QX, Yu XJ. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. *Br J Surg* 2016; **103**: 1189-1199 [PMID: 27256393 DOI: 10.1002/bjs.10187]

36 **Szafranska AE**, Doleshal M, Edmunds HS, Gordon S, Luttges J, Munding JB, Barth RJ Jr, Gutmann EJ, Suriawinata AA, Marc Pipas J, Tannapfel A, Korc M, Hahn SA, Labourier E, Tsongalis GJ. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. *Clin Chem* 2008; **54**: 1716-1724 [PMID: 18719196 DOI: 10.1373/clinchem.2008.109603]

37 **Munding JB**, Adai AT, Maghnouj A, Urbanik A, Zöllner H, Liffers ST, Chromik AM, Uhl W, Szafranska-Schwarzbach AE, Tannapfel A, Hahn SA. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. *Int J Cancer* 2012; **131**: E86-E95 [PMID: 21953293 DOI: 10.1002/ijc.26466]

38 **Frampton AE**, Krell J, Prado MM, Gall TM, Abbassi-Ghadi N, Del Vecchio Blanco G, Funel N, Giovannetti E, Castellano L, Basyouny M, Habib NA, Kaltsidis H, Vlavianos P, Stebbing J, Jiao LR. Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. *Oncotarget* 2016; **7**: 28556-28569 [PMID: 27086919 DOI: 10.18632/oncotarget.8699]

39 **Chung KH,** Ryu JK, Park JM, Lee JM, Lee SH, Kim YH. Sa1942 MicroRNA expression in unresectable pancreatic cancer as a prognostic marker in EUS-FNA cytology specimens. *Gastroenterol* 2014; **146**: S-335 [DOI:10.1016/S0016-5085(14)61211-7]

40 **Preis M**, Gardner TB, Gordon SR, Pipas JM, Mackenzie TA, Klein EE, Longnecker DS, Gutmann EJ, Sempere LF, Korc M. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. *Clin Cancer Res* 2011; **17**: 5812-5821 [PMID: 21652542 DOI: 10.1158/1078-0432.CCR-11-0695]

41 **Panarelli NC**, Chen YT, Zhou XK, Kitabayashi N, Yantiss RK. MicroRNA expression aids the preoperative diagnosis of pancreatic ductal adenocarcinoma. *Pancreas* 2012; **41**: 685-690 [PMID: 22466166 DOI: 10.1097/MPA.0b013e318243a905]

42 **Brand RE**, Adai AT, Centeno BA, Lee LS, Rateb G, Vignesh S, Menard C, Wiechowska-Kozłowska A, Bołdys H, Hartleb M, Sanders MK, Munding JB, Tannapfel A, Hahn SA, Stefańczyk L, Tsongalis GJ, Whitcomb DC, Conwell DL, Morisset JA, Gardner TB, Gordon SR, Suriawinata AA, Lloyd MB, Wylie D, Labourier E, Andruss BF, Szafranska-Schwarzbach AE. A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer. *Clin Gastroenterol Hepatol* 2014; **12**: 1717-1723 [PMID: 24662333 DOI: 10.1016/j.cgh.2014.02.038]

43 **Farrell JJ**, Toste P, Wu N, Li L, Wong J, Malkhassian D, Tran LM, Wu X, Li X, Dawson D, Wu H, Donahue TR. Endoscopically acquired pancreatic cyst fluid microRNA 21 and 221 are associated with invasive cancer. *Am J Gastroenterol* 2013; **108**: 1352-1359 [PMID: 23752880 DOI: 10.1038/ajg.2013.167]

44 **Vila-Navarro E**, Vila-Casadesús M, Moreira L, Duran-Sanchon S, Sinha R, Ginés À, Fernández-Esparrach G, Miquel R, Cuatrecasas M, Castells A, Lozano JJ, Gironella M. MicroRNAs for Detection of Pancreatic Neoplasia: Biomarker Discovery by Next-generation Sequencing and Validation in 2 Independent Cohorts. *Ann Surg* 2017; **265**: 1226-1234 [PMID: 27232245 DOI: 10.1097/SLA.0000000000001809]

45 **Kawano M**, Kaino S, Amano S, Shinoda S, Suenaga S, Sen-Yo M, Sakaida I. Heat Shock Protein 27 Expression in EUS-FNA Samples Can Predict Gemcitabine Sensitivity in Pancreatic Cancer. *In Vivo* 2018; **32**: 637-642 [PMID: 29695571 DOI: 10.21873/invivo.11286]

46 **Ma G**, Sun Y, Fu S. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer. *Int J Clin Exp Pathol* 2015; **8**: 13284-13288 [PMID: 26722531]

47 **Farrell JJ**, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. *Gastroenterology* 2009; **136**: 187-195 [PMID: 18992248 DOI: 10.1053/j.gastro.2008.09.067]

48 **Maréchal R**, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Salmon I, Devière J, Van Laethem JL. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. *Cancer* 2010; **116**: 5200-5206 [PMID: 20669326 DOI: 10.1002/cncr.25303]

49 **Nakahira S**, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa I, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. *Int J Cancer* 2007; **120**: 1355-1363 [PMID: 17131328 DOI: 10.1002/ijc.22390]

50 **Itoi T**, Sofuni A, Fukushima N, Itokawa F, Tsuchiya T, Kurihara T, Moriyasu F, Tsuchida A, Kasuya K. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. *J Gastroenterol* 2007; **42**: 389-394 [PMID: 17530364 DOI: 10.1007/s00535-007-2017-0]

51 **Yamada R**, Mizuno S, Uchida K, Yoneda M, Kanayama K, Inoue H, Murata Y, Kuriyama N, Kishiwada M, Usui M, Ii N, Tsuboi J, Tano S, Hamada Y, Tanaka K, Horiki N, Ogura T, Shiraishi T, Takei Y, Katayama N, Isaji S. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy. *Pancreas* 2016; **45**: 761-771 [PMID: 26784908 DOI: 10.1097/MPA.0000000000000597]

52 **Fujita H**, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. *Neoplasia* 2010; **12**: 807-817 [PMID: 20927319 DOI: 10.1593/neo.10458]

53 **Fujita H**, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Hayashi A, Souzaki R, Tajiri T, Onimaru M, Manabe T, Ohtsuka T, Tanaka M. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. *Int J Oncol* 2011; **38**: 629-641 [PMID: 21243324 DOI: 10.3892/ijo.2011.908]

54 **Saif MW**, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, Carpenter M, Blanquicett C, Diasio RB, Johnson MR. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. *J Clin Oncol* 2005; **23**: 8679-8687 [PMID: 16314628 DOI: 10.1200/JCO.2005.02.0628]

55 **Perales-Patón J**, Piñeiro-Yañez E, Tejero H, López-Casas PP, Hidalgo M, Gómez-López G, Al-Shahrour F. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective. *Public Health Genomics* 2017; **20**: 81-91 [PMID: 28858862 DOI: 10.1159/000479812]

56 **Bardeesy N**, DePinho RA. Pancreatic cancer biology and genetics. *Nat Rev Cancer* 2002; **2**: 897-909 [PMID: 12459728 DOI: 10.1038/nrc949]

57 **Allaway RJ**, Fischer DA, de Abreu FB, Gardner TB, Gordon SR, Barth RJ, Colacchio TA, Wood M, Kacsoh BZ, Bouley SJ, Cui J, Hamilton J, Choi JA, Lange JT, Peterson JD, Padmanabhan V, Tomlinson CR, Tsongalis GJ, Suriawinata AA, Greene CS, Sanchez Y, Smith KD. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites. *Oncotarget* 2016; **7**: 17087-17102 [PMID: 26934555 DOI: 10.18632/oncotarget.7718]

58 **Kim MP**, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. *Nat Protoc* 2009; **4**: 1670-1680 [PMID: 19876027 DOI: 10.1038/nprot.2009.171]

59 **Weeber F**, van de Wetering M, Hoogstraat M, Dijkstra KK, Krijgsman O, Kuilman T, Gadellaa-van Hooijdonk CG, van der Velden DL, Peeper DS, Cuppen EP, Vries RG, Clevers H, Voest EE. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. *Proc Natl Acad Sci U S A* 2015; **112**: 13308-13311 [PMID: 26460009 DOI: 10.1073/pnas.1516689112]

60 **Tiriac H**, Bucobo JC, Tzimas D, Grewel S, Lacomb JF, Rowehl LM, Nagula S, Wu M, Kim J, Sasson A, Vignesh S, Martello L, Munoz-Sagastibelza M, Somma J, Tuveson DA, Li E, Buscaglia JM. Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. *Gastrointest Endosc* 2018; **87**: 1474-1480 [PMID: 29325707 DOI: 10.1016/j.gie.2017.12.032]

61 **Seino T**, Kawasaki S, Shimokawa M, Tamagawa H, Toshimitsu K, Fujii M, Ohta Y, Matano M, Nanki K, Kawasaki K, Takahashi S, Sugimoto S, Iwasaki E, Takagi J, Itoi T, Kitago M, Kitagawa Y, Kanai T, Sato T. Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. *Cell Stem Cell* 2018; **22**: 454-467.e6 [PMID: 29337182 DOI: 10.1016/j.stem.2017.12.009]

62 **Tiriac H**, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, Palmaira RLD, Javed AA, Huynh JC, Johnson M, Arora K, Robine N, Shah M, Sanghvi R, Goetz AB, Lowder CY, Martello L, Driehuis E, LeComte N, Askan G, Iacobuzio-Donahue CA, Clevers H, Wood LD, Hruban RH, Thompson E, Aguirre AJ, Wolpin BM, Sasson A, Kim J, Wu M, Bucobo JC, Allen P, Sejpal DV, Nealon W, Sullivan JD, Winter JM, Gimotty PA, Grem JL, DiMaio DJ, Buscaglia JM, Grandgenett PM, Brody JR, Hollingsworth MA, O’Kane GM, Notta F, Kim E, Crawford JM, Devoe C, Ocean A, Wolfgang CL, Yu KH, Li E, Vakoc CR, Hubert B, Fischer SE, Wilson JM, Moffitt R, Knox J, Krasnitz A, Gallinger S, Tuveson DA. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. *Cancer Discov* 2018; **8**: 1112-1129 [PMID: 29853643 DOI: 10.1158/2159-8290.CD-18-0349]

63 **Seufferlein T**, Kleger A. Organoidomics – falling star or new galaxy in pancreatic cancer? *Nat Rev Gastroenterol Hepatol* 2018; **15**: 586-587 [PMID: 30046146 DOI: 10.1038/s41575-018-0052-3]

64 **Seufferlein T**, Hammel P, Delpero JR, Macarulla T, Pfeiffer P, Prager GW, Reni M, Falconi M, Philip PA, Van Cutsem E. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. *Cancer Treat Rev* 2019; **77**: 1-10 [PMID: 31163334 DOI: 10.1016/j.ctrv.2019.05.007]

65 **Singh RR**, Goldberg J, Varghese AM, Yu KH, Park W, O’Reilly EM. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. *Cancer Treat Rev* 2019; **75**: 27-38 [PMID: 30927677 DOI: 10.1016/j.ctrv.2019.03.003]

66 **Collisson EA**, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. *Nat Rev Gastroenterol Hepatol* 2019; **16**: 207-220 [PMID: 30718832 DOI: 10.1038/s41575-019-0109-y]

**P-Reviewer:** Petrucciani N, Sperti C **S-Editor:** Zhang L

**L-Editor:** Wang TQ **E-Editor:** Qi LL

**Specialty type:** Oncology

**Country of origin:** Italy

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1** **Main pitfalls towards the optimization and standardization of the use of endoscopic ultrasound-obtained material for molecular investigations**

|  |  |
| --- | --- |
| **Endoscopic ultrasound obtained material for molecular investigations** | **Main pitfalls** |
| DNA and RNA extraction and use for molecular investigations | Needle choice |
| Sample storage |
| Cellularity and contamination |
| RNA degradation |
| Intratumoral heterogeneity |
| Total amount of tumoral cells |
| Lesional-to-non-lesional cell ratio |
| Molecular modifications during disease course |
| Generation of patient-derived xenografts | Expensive |
| Time- and resource-consuming |
| Low engraftment rates |
| Generation of organoids | Lack of standardization |
| Lack of immune cells, blood vessels, and stromal components |

DNA: Deoxyribonucleic acid; RNA: Ribonucleic acid.